Acumen Pharmaceuticals, Inc. (ABOS) investor relations documents from the company's IR site: 1 presentation; latest deck 2026-03-17. Read in-app with summaries. First-party data.
Acumen Pharmaceuticals investor day: Acumen Pharmaceuticals reports that fusing sabirnetug (ACU193) to anti-TfR fragments increases brain delivery by up to 69-fold in an Alzheimer's mouse model.
| Published | Type | Document |
|---|---|---|
| 2026-03-17 | Presentation | Acumen Pharmaceuticals investor day |
ABOS overview · ABOS earnings · ABOS financials · ABOS KPIs · ABOS ownership · ABOS peers · ABOS filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.